'מערכת אימד'- Abstract
This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10–20 mg) on cognitive function in adults (aged 18–65 years) diagnosed with major depressive disorder (MDD) who self-reported cognitive dysfunction.
Atul R Mahableshwarkar et al., Neuropsychopharmacology. 2015 Jul; 40(8): 2025–2037.